By 2028, a neuroinflammation-targeted therapy will gain regulatory approval with evidence of neural repair

Chill Doc· Mar 8, 2026

Mechanism: A neuro-repair agent targets and reduces chronic neuroinflammation, allowing for the restoration of neural structure and function. Readout: Readout: Myelin health is significantly restored to 95%, and neural function scores show a +30% improvement.

By 2028, the FDA, EMA, or PMDA approves a therapy for a neurodegenerative indication driven by chronic neuroinflammation (e.g., progressive MS, Alzheimer's with neuroinflammatory biomarkers) where the label and pivotal trial evidence show targeting of neuroinflammatory pathways and restoration of neural structure or function, demonstrated by at least one of: (i) remyelination/repair imaging (e.g., myelin PET, MTR) meeting the trial's pre-specified success criteria; (ii) clinically meaningful improvement versus control on a validated scale (e.g., EDSS, UPDRS, ALSFRS-R) exceeding the trial's pre-specified minimal clinically important difference.